G protein-coupled receptors in cardiac biology: old and new receptors

Biophysical Reviews

Volumn 7, Issue 1, 2015, Pages 77-89

  Foster, Simon R ^a   Roura, Eugeni ^a   Molenaar, Peter ^a,b   Thomas, Walter G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Cardiovascular disease; G protein coupled receptor; Heart; Odorant receptor; Orphan receptor; Taste receptor

Indexed keywords

ADENOSINE RECEPTOR; ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ENDOTHELIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; MUSCARINIC RECEPTOR; OPIATE RECEPTOR; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; HEART FAILURE; HUMAN; HYPERTENSION; OLFACTORY RECEPTOR; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 84922422565     PISSN: 18672450     EISSN: 18672469     Source Type: Journal    
DOI: 10.1007/s12551-014-0154-2     Document Type: Article

References (160)

1. Adler E, Hoon MA, Mueller KL, Chandrashekar J, Ryba NJP, Zuker CS (2000) A novel family of mammalian taste receptors. Cell 100:693–702
2. Albizu L, Cottet M, Kralikova M, Stoev S, Seyer R, Brabet I, Roux T, Bazin H, Bourrier E, Lamarque L, Breton C, Rives ML, Newman A, Javitch J, Trinquet E, Manning M, Pin JP, Mouillac B, Durroux T (2010) Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat Chem Biol 6:587–594
3. A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364:347–354
4. Asano K, Bohlmeyer TJ, Westcott JY, Zisman L, Kinugawa K, Good M, Minobe WA, Roden R, Wolfel EE, Lindenfeld J, David Port J, Perryman MB, Clevel J, Lowes BD, Bristow MR (2002) Altered expression of endothelin receptors in failing human left ventricles. J Mol Cell Cardiol 34:833–846
5. Audet M, Bouvier M (2012) Restructuring G-protein- coupled receptor activation. Cell 151:14–23
6. Bader M (2010) Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 50:439–465
7. Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC (1964) A new adrenergic beta receptor antagonist. Lancet 1:1080–1081
8. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516–1525
9. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett JC Jr (2011) Cardiorenal actions of TRV120027, a novel b-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 4:770–778
10. Boerrigter G, Soergel DG, Violin JD, Lark MW, Burnett JC Jr (2012) TRV120027, a novel beta-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail 5:627–634
11. Brinks HL, Eckhart AD (2010) Regulation of GPCR signaling in hypertension. Biochim Biophys Acta Biomembr 1802:1268–1275
12. Bristow MR (2000) Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101:558–569
13. Bristow MR (2011) Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res 109:1176–1194
14. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307:205–211
15. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB (1986) Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59:297–309
16. Buck L, Axel R (1991) A novel multigene family may encode odorant receptors: a molecular basis for odor recognition. Cell 65:175–187
17. Burrell KM, Molenaar P, Dawson PJ, Kaumann AJ (2000) Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther 292:449–459
18. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, Trendelenburg U (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121–136
19. Chan HW, Jenkins A, Pipolo L, Hannan RD, Thomas WG, Smith NJ (2006) Effect of dominant-negative epidermal growth factor receptors on cardiomyocyte hypertrophy. J Recept Signal Transduct Res 26:659–677
20. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, Felder CC (2008) Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 105:10978–10983
21. Chen L, Meyers D, Javorsky G, Burstow D, Lolekha P, Lucas M, Semmler AB, Savarimuthu SM, Fong KM, Yang IA, Atherton J, Galbraith AJ, Parsonage WA, Molenaar P (2007) Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics 17:941–949
22. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318:1258–1265
23. Civelli O, Reinscheid RK, Zhang Y, Wang Z, Fredriksson R, Schioth HB (2013) G protein-coupled receptor deorphanizations. Annu Rev Pharmacol Toxicol 53:127–146
24. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819–823
25. Cottingham C, Chen Y, Jiao K, Wang Q (2011) The antidepressant desipramine is an arrestin-biased ligand at the alpha(2A)-adrenergic receptor driving receptor down-regulation in vitro and in vivo. J Biol Chem 286:36063–36075
26. Daaka Y, Luttrell LM, Lefkowitz RJ (1997) Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390:88–91
27. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415–472
28. Deshpande DA, Wang WCH, McIlmoyle EL, Robinett KS, Schillinger RM, An SS, Sham JSK, Liggett SB (2010) Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction. Nat Med 16:1299–1304
29. DeWire SM, Violin JD (2011) Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res 109:205–216
30. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483–510
31. DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen X-T, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD (2013) A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344:708–717
32. Dixon RA, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, Frielle T, Bolanowski MA, Bennett CD, Rands E, Diehl RE, Mumford RA, Slater EE, Sigal IS, Caron MG, Lefkowitz RJ, Strader CD (1986) Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 321:75–79
33. Donato M, Gelpi RJ (2003) Adenosine and cardioprotection during reperfusion—an overview. Mol Cell Biochem 251:153–159
34. Dror RO, Arlow DH, Maragakis P, Mildorf TJ, Pan AC, Xu H, Borhani DW, Shaw DE (2011a) Activation mechanism of the beta2-adrenergic receptor. Proc Natl Acad Sci USA 108:18684–18689
35. Dror RO, Pan AC, Arlow DH, Borhani DW, Maragakis P, Shan Y, Xu H, Shaw DE (2011b) Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci USA 108:13118–13123
36. Dror RO, Green HF, Valant C, Borhani DW, Valcourt JR, Pan AC, Arlow DH, Canals M, Lane JR, Rahmani R, Baell JB, Sexton PM, Christopoulos A, Shaw DE (2013) Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 503:295–299
37. Drutel G, Arrang JM, Diaz J, Wisnewsky C, Schwartz K, Schwartz JC (1995) Cloning of OL1, a putative olfactory receptor and its expression in the developing rat heart. Receptors Channels 3:33–40
38. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ (2010) Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 7:48–58
39. Du L, Gao ZG, Nithipatikom K, Ijzerman AP, Veldhoven JP, Jacobson KA, Gross GJ, Auchampach JA (2012) Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A(3) adenosine receptor. J Pharmacol Exp Ther 340:210–217
40. Einstein R, Jordan H, Zhou W, Brenner M, Moses EG, Liggett SB (2008) Alternative splicing of the G protein-coupled receptor superfamily in human airway smooth muscle diversifies the complement of receptors. Proc Natl Acad Sci USA 105:5230–5235
41. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11:1170–1172
42. Ferrand N, Pessah M, Frayon S, Marais J, Garel JM (1999) Olfactory receptors, Golf alpha and adenylyl cyclase mRNA expressions in the rat heart during ontogenic development. J Mol Cell Cardiol 31:1137–1142
43. Flegel C, Manteniotis S, Osthold S, Hatt H, Gisselmann G (2013) Expression profile of ectopic olfactory receptors determined by deep sequencing. PLoS ONE 8:e55368
44. Foster SR, Porrello ER, Purdue B, Chan H-W, Voigt A, Frenzel S, Hannan RD, Moritz KM, Simmons DG, Molenaar P, Roura E, Boehm U, Meyerhof W, Thomas WG (2013) Expression, regulation and putative nutrient-sensing function of taste GPCRs in the heart. PLoS ONE 8:e64579
45. Foster SR, Blank K, See Hoe LE, Behrens M, Meyerhof W, Peart JN, Thomas WG (2014a) Bitter taste receptor agonists elicit G-protein-dependent negative inotropy in the murine heart. FASEB J 28:4497–4508
46. Foster SR, Roura E, Thomas WG (2014b) Extrasensory perception: odorant and taste receptors beyond the nose and mouth. Pharmacol Ther 142:41–61
47. Fu Q, Chen X, Xiang YK (2013) Compartmentalization of beta-adrenergic signals in cardiomyocytes. Trends Cardiovasc Med 23:250–256
48. George AJ, Thomas WG, Hannan RD (2010) The renin–angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 10:745–759
49. Gesty-Palmer D, Flannery P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ, Luttrell LM (2009) A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 1:1ra1
50. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB (2014) Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129:399–410
51. Goupil E, Tassy D, Bourguet C, Quiniou C, Wisehart V, Petrin D, Le Gouill C, Devost D, Zingg HH, Bouvier M, Saragovi HU, Chemtob S, Lubell WD, Claing A, Hebert TE, Laporte SA (2010) A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathway. J Biol Chem 285:25624–25636
52. Griffin CA, Kafadar KA, Pavlath GK (2009) MOR23 promotes muscle regeneration and regulates cell adhesion and migration. Dev Cell 17:649–661
53. Gudermann T, Kalkbrenner F, Schultz G (1996) Diversity and selectivity of receptor-G protein interaction. Annu Rev Pharmacol Toxicol 36:429–459
54. Gurevich EV, Tesmer JJ, Mushegian A, Gurevich VV (2012) G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol Ther 133:40–69
55. Hakak Y, Shrestha D, Goegel MC, Behan DP, Chalmers DT (2003) Global analysis of G-protein-coupled receptor signaling in human tissues. FEBS Lett 550:11–17
56. Hamm HE (1998) The many faces of G protein signaling. J Biol Chem 273:669–672
57. Harris DM, Cohn HI, Pesant S, Eckhart AD (2008) GPCR signalling in hypertension: role of GRKs. Clin Sci (Lond) 115:79–89
58. Headrick JP, Pepe S, Peart JN (2012) Non-analgesic effects of opioids: cardiovascular effects of opioids and their receptor systems. Curr Pharm Des 18:6090–6100
59. Headrick JP, Ashton KJ, Rose’meyer RB, Peart JN (2013) Cardiovascular adenosine receptors: expression, actions and interactions. Pharmacol Ther 140:92–111
60. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN (2004) Comparative pharmacology of human beta-adrenergic receptor subtypes–characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 369:151–159
61. Hollenstein K, Kean J, Bortolato A, Cheng RK, Dore AS, Jazayeri A, Cooke RM, Weir M, Marshall FH (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499:438–443
62. Holloway AC, Qian H, Pipolo L, Ziogas J, Miura S, Karnik S, Southwell BR, Lew MJ, Thomas WG (2002) Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol 61:768–777
63. Insel PA (2003) Location, location, location. Trends Endocrinol Metab 14:100–102
64. Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, Zhou J, Kim HH, Xu X, Chan SL, Juhaszova M, Bernier M, Mosinger B, Margolskee RF, Egan JM (2007) Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA 104:15069–15074
65. Jenkins L, Harries N, Lappin JE, MacKenzie AE, Neetoo-Isseljee Z, Southern C, McIver EG, Nicklin SA, Taylor DL, Milligan G (2012) Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther 343:683–695
66. Kaoukis A, Deftereos S, Raisakis K, Giannopoulos G, Bouras G, Panagopoulou V, Papoutsidakis N, Cleman MW, Stefanadis C (2013) The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition. Curr Top Med Chem 13:95–114
67. Katritch V, Cherezov V, Stevens RC (2013) Structure–function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 53:531–556
68. Kaumann A, Bartel S, Molenaar P, Sanders L, Burrell K, Vetter D, Hempel P, Karczewski P, Krause EG (1999) Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 99:65–72
69. Kenakin T, Christopoulos A (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12:205–216
70. Kenakin T, Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265–304
71. Kilts JD, Gerhardt MA, Richardson MD, Sreeram G, Mackensen GB, Grocott HP, White WD, Davis RD, Newman MF, Reves JG, Schwinn DA, Kwatra MM (2000) Beta(2)-adrenergic and several other G protein-coupled receptors in human atrial membranes activate both G(s) and G(i). Circ Res 87:705–709
72. Kobilka BK, Deupi X (2007) Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28:397–406
73. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, Sexton PM (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78:456–465
74. Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hubner H, Pardon E, Valant C, Sexton PM, Christopoulos A, Felder CC, Gmeiner P, Steyaert J, Weis WI, Garcia KC, Wess J, Kobilka BK (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504:101–106
75. Lagerstrom MC, Schioth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7:339–357
76. Lee RJ, Xiong G, Kofonow JM, Chen B, Lysenko A, Jiang P, Abraham V, Doghramji L, Adappa ND, Palmer JN, Kennedy DW, Beauchamp GK, Doulias PT, Ischiropoulos H, Kreindler JL, Reed DR, Cohen NA (2012) T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection. J Clin Invest 122:4145–4159
77. Lefkowitz RJ, Mukherjee C, Coverstone M, Caron MG (1974) Stereospecific (3H) (minus)-alprenolol binding sites, beta-adrenergic receptors and adenylate cyclase. Biochem Biophys Res Commun 60:703–709
78. Leung T, Humbert JE, Stauffer AM, Giger KE, Chen H, Tsai HJ, Wang C, Mirshahi T, Robishaw JD (2008) The orphan G protein-coupled receptor 161 is required for left-right patterning. Dev Biol 323:31–40
79. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 103:11288–11293
80. Logothetis DE, Kurachi Y, Galper J, Neer EJ, Clapham DE (1987) The beta gamma subunits of GTP-binding proteins activate the muscarinic K+ channel in heart. Nature 325:321–326
81. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ (1990) beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 248:1547–1550
82. Luttrell LM (2008) Reviews in molecular biology and biotechnology: Transmembrane signaling by G protein-coupled receptors. Mol Biotechnol 39:239–264
83. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, Caron MG, Lefkowitz RJ (1999) Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283:655–661
84. Lymperopoulos A, Rengo G, Koch WJ (2012) GRK2 inhibition in heart failure: something old, something new. Curr Pharm Des 18:186–191
85. Mace OJ, Lister N, Morgan E, Shepherd E, Affleck J, Helliwell P, Bronk JR, Kellett GL, Meredith D, Boyd R, Pieri M, Bailey PD, Pettcrew R, Foley D (2009) An energy supply network of nutrient absorption coordinated by calcium and T1R taste receptors in rat small intestine. J Physiol 587:195–210
86. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP (2009) [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 54:598–604
87. Mason DA, Moore JD, Green SA, Liggett SB (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274:12670–12674
88. May LT, Leach K, Sexton PM, Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1–51
89. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, Conn PJ, Lindsley CW (2012) Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem 55:1445–1464
90. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW, Liggett SB (2003) Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9:1300–1305
91. Millar RP, Newton CL (2010) The year in G protein-coupled receptor research. Mol Endocrinol 24:261–274
92. Milligan G (2007) G protein-coupled receptor dimerisation: molecular basis and relevance to function. Biochim Biophys Acta Biomembr 1768:825–835
93. Milligan G, White JH (2001) Protein-protein interactions at G-protein-coupled receptors. Trends Pharmacol Sci 22:513–518
94. Min KD, Asakura M, Liao Y, Nakamaru K, Okazaki H, Takahashi T, Fujimoto K, Ito S, Takahashi A, Asanuma H, Yamazaki S, Minamino T, Sanada S, Seguchi O, Nakano A, Ando Y, Otsuka T, Furukawa H, Isomura T, Takashima S, Mochizuki N, Kitakaze M (2010) Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochem Biophys Res Commun 393:55–60
95. Molenaar P, Parsonage WA (2005) Fundamental considerations of beta-adrenoceptor subtypes in human heart failure. Trends Pharmacol Sci 26:368–375
96. Molenaar P, Bartel S, Cochrane A, Vetter D, Jalali H, Pohlner P, Burrell K, Karczewski P, Krause EG, Kaumann A (2000) Both beta(2)- and beta(1)-adrenergic receptors mediate hastened relaxation and phosphorylation of phospholamban and troponin I in ventricular myocardium of Fallot infants, consistent with selective coupling of beta(2)-adrenergic receptors to G(s)-protein. Circulation 102:1814–1821
97. Molenaar P, Christ T, Ravens U, Kaumann A (2006) Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart. Cardiovasc Res 69:128–139
98. Molenaar P, Savarimuthu SM, Sarsero D, Chen L, Semmler AB, Carle A, Yang I, Bartel S, Vetter D, Beyerdorfer I, Krause EG, Kaumann AJ (2007) (−)-Adrenaline elicits positive inotropic, lusitropic, and biochemical effects through beta2 -adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with Gs coupling but not with Gi coupling. Naunyn Schmiedebergs Arch Pharmacol 375:11–28
99. Molenaar P, Christ T, Hussain RI, Engel A, Berk E, Gillette KT, Chen L, Galindo-Tovar A, Krobert KA, Ravens U, Levy FO, Kaumann AJ (2013) PDE3, but not PDE4, reduces beta(1) - and beta(2) -adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients. Br J Pharmacol 169:528–538
100. Molenaar P, Christ T, Berk E, Engel A, Gillette KT, Galindo-Tovar A, Ravens U, Kaumann AJ (2014) Carvedilol induces greater control of beta2- than beta 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium. Naunyn Schmiedebergs Arch Pharmacol 387:629–640
101. Monasky MM, Taglieri DM, Henze M, Warren CM, Utter MS, Soergel DG, Violin JD, Solaro RJ (2013) The beta-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium. Am J Physiol Heart Circ Physiol 305:H856–H866
102. Moore-Morris T, Varrault A, Mangoni ME, Le Digarcher A, Negre V, Dantec C, Journot L, Nargeot J, Couette B (2009) Identification of potential pharmacological targets by analysis of the comprehensive G protein-coupled receptor repertoire in the four cardiac chambers. Mol Pharmacol 75:1108–1116
103. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE (1991) Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351:233–236
104. Neetoo-Isseljee Z, MacKenzie AE, Southern C, Jerman J, McIver EG, Harries N, Taylor DL, Milligan G (2013) High-throughput identification and characterization of novel, species-selective GPR35 agonists. J Pharmacol Exp Ther 344:568–578
105. Nelson G, Hoon MA, Chandrashekar J, Zhang YF, Ryba NJP, Zuker CS (2001) Mammalian sweet taste receptors. Cell 106:381–390
106. Nelson G, Chandrashekar J, Hoon MA, Feng LX, Zhao G, Ryba NJP, Zuker CS (2002) An amino-acid taste receptor. Nature 416:199–202
107. Neuhaus EM, Zhang WY, Gelis L, Deng Y, Noldus J, Hatt H (2009) Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J Biol Chem 284:16218–16225
108. Neumann J, Schmitz W, Scholz H, von Meyerinck L, Doring V, Kalmar P (1988) Increase in myocardial Gi-proteins in heart failure. Lancet 2:936–937
109. Nikolaev VO, Moshkov A, Lyon AR, Miragoli M, Novak P, Paur H, Lohse MJ, Korchev YE, Harding SE, Gorelik J (2010) Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 327:1653–1657
110. Noda K, Feng YH, Liu XP, Saad Y, Husain A, Karnik SS (1996) The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 35:16435–16442
111. Nygaard R, Zou Y, Dror RO, Mildorf TJ, Arlow DH, Manglik A, Pan AC, Liu CW, Fung JJ, Bokoch MP, Thian FS, Kobilka TS, Shaw DE, Mueller L, Prosser RS, Kobilka BK (2013) The dynamic process of beta(2)-adrenergic receptor activation. Cell 152:532–542
112. Oro C, Qian H, Thomas WG (2007) Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther 113:210–226
113. Ostrom RS, Insel PA (2004) The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology. Br J Pharmacol 143:235–245
114. Parameswaran N, Spielman WS (2006) RAMPs: the past, present and future. Trends Biochem Sci 31:631–638
115. Peart JN, Gross GJ (2006) Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways. Am J Physiol Heart Circ Physiol 291:H1746–H1753
116. Perez D, Hébert T, Cotecchia S, Doze VA, Graham RM, Bylund DB, Altosaar K, Devost D, Gora S, Goupil E, Kan S, Machkalyan G, Sleno R, Zylbergold P, Balaji P, Bond RA, Eikenburg DC, Hieble JP, Minneman KP, Parra S, Hills R (2014) Adrenoceptors. IUPHAR database (IUPHAR-DB). Available at: http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=4
117. Pluznick JL, Zou DJ, Zhang XH, Yan QS, Rodriguez-Gil DJ, Eisner C, Wells E, Greer CA, Wang T, Firestein S, Schnermann J, Caplan MJ (2009) Functional expression of the olfactory signaling system in the kidney. Proc Natl Acad Sci USA 106:2059–2064
118. Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, Brunet I, Wan LX, Rey F, Wang T, Firestein SJ, Yanagisawa M, Gordon JI, Eichmann A, Peti-Peterdi J, Caplan MJ (2013) Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA 110:4410–4415
119. Rask-Andersen M, Almen MS, Schioth HB (2011) Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 10:579–590
120. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, Mathiesen JM, Shah ST, Lyons JA, Caffrey M, Gellman SH, Steyaert J, Skiniotis G, Weis WI, Sunahara RK, Kobilka BK (2011) Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477:549–555
121. Regard JB, Sato IT, Coughlin SR (2008) Anatomical profiling of G protein-coupled receptor expression. Cell 135:561–571
122. Rockman HA, Koch WJ, Lefkowitz RJ (2002) Seven-transmembrane-spanning receptors and heart function. Nature 415:206–212
123. Rodbell M (1995) Nobel lecture. Signal transduction: evolution of an idea. Biosci Rep 15:117–133
124. Ronkainen VP, Tuomainen T, Huusko J, Laidinen S, Malinen M, Palvimo JJ, Yla-Herttuala S, Vuolteenaho O, Tavi P (2014) Hypoxia-inducible factor 1-induced G protein-coupled receptor 35 expression is an early marker of progressive cardiac remodelling. Cardiovasc Res 101:69–77
125. Salazar NC, Chen J, Rockman HA (2007) Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim Biophys Acta Biomembr 1768:1006–1018
126. Schmid CL, Raehal KM, Bohn LM (2008) Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA 105:1079–1084
127. Scimia MC, Hurtado C, Ray S, Metzler S, Wei K, Wang J, Woods CE, Purcell NH, Catalucci D, Akasaka T, Bueno OF, Vlasuk GP, Kaliman P, Bodmer R, Smith LH, Ashley E, Mercola M, Brown JH, Ruiz-Lozano P (2012) APJ acts as a dual receptor in cardiac hypertrophy. Nature 488:394–398
128. Scimia MC, Blass BE, Koch WJ (2014) Apelin receptor: its responsiveness to stretch mechanisms and its potential for cardiovascular therapy. Expert Rev Cardiovasc Ther 12:733–741
129. Shoichet BK, Kobilka BK (2012) Structure-based drug screening for G-protein-coupled receptors. Trends Pharmacol Sci 33:268–272
130. Shukla AK, Manglik A, Kruse AC, Xiao K, Reis RI, Tseng WC, Staus DP, Hilger D, Uysal S, Huang LY, Paduch M, Tripathi-Shukla P, Koide A, Koide S, Weis WI, Kossiakoff AA, Kobilka BK, Lefkowitz RJ (2013) Structure of active beta-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature 497:137–141
131. Siu FY, He M, de Graaf C, Han GW, Yang D, Zhang Z, Zhou C, Xu Q, Wacker D, Joseph JS, Liu W, Lau J, Cherezov V, Katritch V, Wang MW, Stevens RC (2013) Structure of the human glucagon class B G-protein-coupled receptor. Nature 499:444–449
132. Smith NJ, Chan HW, Qian H, Bourne AM, Hannan KM, Warner FJ, Ritchie RH, Pearson RB, Hannan RD, Thomas WG (2011) Determination of the exact molecular requirements for type 1 angiotensin receptor epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy. Hypertension 57:973–980
133. Snead AN, Insel PA (2012) Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts. FASEB J 26:4540–4547
134. Spaethling JM, Piel D, Dueck H, Buckley PT, Morris JF, Fisher SA, Lee J, Sul JY, Kim J, Bartfai T, Beck SG, Eberwine JH (2014) Serotonergic neuron regulation informed by in vivo single-cell transcriptomics. FASEB J 28:771–780
135. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP (1997) Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. Circulation 95:1918–1929
136. Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysa J, Toth M, Ruskoaho H (2002) Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 91:434–440
137. Tang CM, Insel PA (2004) GPCR expression in the heart - “New” receptors in myocytes and fibroblasts. Trends Cardiovasc Med 14:94–99
138. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381:29–39
139. Thanawala VJ, Forkuo GS, Stallaert W, Leff P, Bouvier M, Bond R (2014) Ligand bias prevents class equality among beta-blockers. Curr Opin Pharmacol 16:50–57
140. Thomas WG, Qian H, Chang CS, Karnik S (2000) Agonist-induced phosphorylation of the angiotensin II (AT(1A)) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state. J Biol Chem 275:2893–2900
141. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian HW, Hannan RD (2002) Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 90:135–142
142. Tilley DG (2011) G protein–dependent and G protein–independent signaling pathways and their impact on cardiac function. Circ Res 109:217–230
143. Tizzano M, Gulbransen BD, Vandenbeuch A, Clapp TR, Herman JP, Sibhatu HM, Churchill ME, Silver WL, Kinnamon SC, Finger TE (2010) Nasal chemosensory cells use bitter taste signaling to detect irritants and bacterial signals. Proc Natl Acad Sci USA 107:3210–3215
144. Vaidehi N, Kenakin T (2010) The role of conformational ensembles of seven transmembrane receptors in functional selectivity. Curr Opin Pharmacol 10:775–781
145. Valant C, May LT, Aurelio L, Chuo CH, White PJ, Baltos JA, Sexton PM, Scammells PJ, Christopoulos A (2014) Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proc Natl Acad Sci USA 111:4614–4619
146. van den Brink OW, Delbridge LM, Rosenfeldt FL, Penny D, Esmore DS, Quick D, Kaye DM, Pepe S (2003) Endogenous cardiac opioids: enkephalins in adaptation and protection of the heart. Heart Lung Circ 12:178–187
147. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM (2013) Molecular signatures of G-protein-coupled receptors. Nature 494:185–194
148. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW (2010) Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335:572–579
149. Violin JD, Soergel DG, Boerrigter G, Burnett JC Jr, Lark MW (2013) GPCR biased ligands as novel heart failure therapeutics. Trends Cardiovasc Med 23:242–249
150. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I (1975) Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022–1036
151. Walker JK, Penn RB, Hanania NA, Dickey BF, Bond RA (2011) New perspectives regarding beta(2) -adrenoceptor ligands in the treatment of asthma. Br J Pharmacol 163:18–28
152. Wang C, Wu H, Katritch V, Han GW, Huang XP, Liu W, Siu FY, Roth BL, Cherezov V, Stevens RC (2013) Structure of the human smoothened receptor bound to an antitumour agent. Nature 497:338–343
153. Wang C, Wu H, Evron T, Vardy E, Han GW, Huang XP, Hufeisen SJ, Mangano TJ, Urban DJ, Katritch V, Cherezov V, Caron MG, Roth BL, Stevens RC (2014) Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs. Nat Commun 5:4355
154. Wilbur SL, Marchlinski FE (1997) Adenosine as an antiarrhythmic agent. Am J Cardiol 79:30–37
155. Wootten D, Christopoulos A, Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12:630–644
156. Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, Niswender CM, Katritch V, Meiler J, Cherezov V, Conn PJ, Stevens RC (2014) Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344:58–64
157. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiroi Y, Mizuno T, Maemura K, Kurihara H, Aikawa R, Takano H, Yazaki Y (1996) Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 271:3221–3228
158. Zhang XM, Rogers M, Tian HK, Zhang XH, Zou DJ, Jian L, Ma MH, Shepherd GM, Firestein SJ (2004) High-throughput microarray detection of olfactory receptor gene expression in the mouse. Proc Natl Acad Sci USA 101:14168–14173
159. Zhang XH, De la Cruz O, Pinto JM, Nicolae D, Firestein S, Gilad Y (2007) Characterizing the expression of the human olfactory receptor gene family using a novel DNA microarray. Genome Biol 8:R86
160. Zhao P, Metcalf M, Bunnett NW (2014) Biased signaling of protease-activated receptors. Front Endocrinol (Lausanne) 5:67